Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name	of entity	ABN/ARSN	
Sign	na Pharmaceuticals Limited	15 088 417 403	
We	(the entity) give ASX the following	ng information.	
Info	ormation about buy-back		
	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012	
	al of all shares/units be eptances have been receiv	Before previous	
		ved, before, and on	, previous day
		Before previous	, previous day
ICC	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been	ved, before, and on Before previous day	Previous day

	Before previous day			Previous day		
ket	Highest \$0.7900	price	paid:	Highest price paid: \$0.7700		
	Lowest	price	paid:	Lowest price paid: \$0.7550		
	\$0.6250	price	paiu.	Highest price allowed under rule 7.33:		

5 If buy-back is an on-market buy-back

How many shares/units may still be bought back?

6	If the company/trust has
	disclosed an intention to buy
	back a maximum number of
	shares/units - the remaining
	number of shares/units to be
	bought back

81,058,669			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Sue Morgan

(Director/Company secretary)

Date: 17 April 2013